Rilematovir API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Rilematovir API 1383450-81-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Rilematovir. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Rilematovir
- Synonyms:
- Cas Number:
- 1383450-81-4
- DrugBank number:
- DB15672
- Unique Ingredient Identifier:
- NQ99E8OH3P
General Description:
Rilematovir, identified by CAS number 1383450-81-4, is a notable compound with significant therapeutic applications. Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).
Categories:
Rilematovir is categorized under the following therapeutic classes: Heterocyclic Compounds, Fused-Ring, Imidazoles. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Rilematovir is a type of Hematopoietic Agents
Hematopoietic agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the treatment of various blood disorders and diseases. These agents stimulate the production, maturation, and function of blood cells, particularly those involved in the process of hematopoiesis, which is the formation of new blood cells.
One of the commonly used hematopoietic agents is erythropoietin, a glycoprotein hormone that regulates red blood cell production. It is employed in the treatment of anemia associated with chronic kidney disease, cancer chemotherapy, and certain other conditions. Another important hematopoietic agent is granulocyte colony-stimulating factor (G-CSF), which stimulates the production of white blood cells known as neutrophils. G-CSF is used to prevent infections in patients undergoing chemotherapy and to enhance the recovery of blood cell counts after bone marrow transplantation.
Thrombopoietin receptor agonists are another class of hematopoietic agents that promote the production of platelets, essential for blood clotting. These agents find applications in the management of thrombocytopenia, a condition characterized by low platelet counts.
Hematopoietic agents are typically administered through injections or infusions, and their dosage and frequency vary depending on the specific indication and patient's response. While these agents provide critical therapeutic benefits, their use requires careful monitoring to ensure optimal efficacy and safety.
In conclusion, hematopoietic agents are vital pharmaceutical APIs used to stimulate the production of blood cells and treat various blood disorders. Their use significantly improves patients' quality of life and plays a crucial role in managing hematological conditions.
